

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



山東威高集團醫用高分子製品股份有限公司
Shandong Weigao Group Medical Polymer Company Limited*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1066)

INSIDE INFORMATION ANNOUNCEMENT SUBMISSION OF DEFINITIVE BID FOR PROPOSED ACQUISITION

This announcement is made by Shandong Weigao Group Medical Polymer Company Limited (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders and potential investors of the Company that the Company together with a financial investor has submitted a definitive bid (the “**Bid**”) to acquire the entire issued share capital of a medical device company (the “**Target Company**”) headquartered in the United States of America (the “**Proposed Acquisition**”). The Target Company is a global manufacturer and marketer of single-use specialty medical devices for interventional procedures.

* For identification purpose only

The Proposed Acquisition, if materialises, will constitute a notifiable transaction of the Company under Chapter 14 of the Listing Rules. The Company will publish further announcement(s) to update its shareholders and investors of the progress of the Bid as and when appropriate and comply with the applicable requirements of the Listing Rules.

The Proposed Acquisition is subject to a bid process the outcome of which is uncertain. The terms of the Proposed Acquisition are yet to be agreed between the parties and therefore, the Proposed Acquisition may or may not eventually materialise. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Shandong Weigao Group Medical Polymer Company Limited
Zhang Huawei
Chairman

31 August 2017

Weihai, Shandong, the PRC

As at the date of this announcement, the Board comprises:

Mr. Zhang Huawei (*Executive Director*)

Mr. Wang Yi (*Executive Director*)

Mr. Gong Jianbo (*Executive Director*)

Mr. Xia Liebo (*Executive Director*)

Mrs. Zhou Shuhua (*Non-executive Director*)

Mr. Lo Wai Hung (*Independent non-executive Director*)

Mrs. Fu Mingzhong (*Independent non-executive Director*)

Mrs. Wang Jinxia (*Independent non-executive Director*)